Kailera Therapeutics closed a $600 million Series B led by Bain Capital Private Equity to support global Phase‑3 trials of KAI‑9531, a weekly injectable targeting the same dual receptor axis as existing blockbuster GLP‑1/GIP programs. The raise will also back additional oral and injectable metabolic candidates in Kailera’s pipeline. Kailera formed last year with sizable early funding; the new capital expedites plans to start Phase 3 testing by year‑end and expands the company’s global development footprint. Investors include sovereign wealth funds and royalty investors, reflecting strong confidence in obesity therapeutics with differentiated pharmacology and dosing profiles. The round is among the largest private financings in obesity biotech this year, reinforcing continued concentration of capital into metabolic indications despite wider market volatility.